Sponsors (10)
Introduced September 2, 2025 by Chris Pappas · Last progress September 2, 2025
The bill restores prior Medicaid rules and preserves the orphan-drug exclusion—protecting beneficiaries and rare-disease access and avoiding some implementation work—while trading off higher drug spending for Medicare/taxpayers and potential funding or operational disruption for states and providers.
Medicaid beneficiaries (low-income and other enrollees) keep prior eligibility and benefit rules, preventing sudden loss of coverage or benefits that would have followed the repealed changes.
State governments and hospitals/health systems avoid having to implement the repealed changes, reducing operational disruption and some implementation costs.
Patients with rare diseases retain the existing exclusion for orphan drugs from the Drug Price Negotiation Program, preserving access to treatments that might be affected by price negotiations.
Medicare beneficiaries and taxpayers may face higher drug spending because orphan drugs remain excluded from price negotiation, keeping prices elevated and putting upward pressure on premiums and federal healthcare budgets.
State governments and hospitals/health systems that began relying on new funding or administrative authorities could suffer budget shortfalls or operational disruption if those resources are withdrawn.
Medicaid beneficiaries could face uncertainty or delays in planned program changes (such as expansions or new services) if those changes are canceled, delaying access to care improvements.
Based on analysis of 3 sections of legislative text.
Repeals two provisions of Public Law 119–21 to restore prior Medicaid law and to restore the orphan‑drug exclusion for the federal Drug Price Negotiation Program, and rescinds related appropriations.
Establishes a short title for the law, then cancels two specific changes made by Public Law 119–21: it removes an amendment to Medicaid law and rescinds the funding tied to that amendment, and it reverses a change to the Drug Price Negotiation Program that had altered the orphan‑drug exclusion. The net effect is to restore prior Medicaid rules and the prior orphan‑drug treatment in the drug negotiation program as if those two prior provisions had never been enacted. This will affect how Medicaid is administered and funded at the federal level, how the drug negotiation program applies to orphan drugs, and federal outlays tied to the rescinded appropriations. States, patients who rely on Medicaid, people taking orphan drugs, and drug manufacturers are the most directly affected parties, and administrative agencies would apply the earlier statutory rules going forward.